Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics. Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About the 12th Annual Conference on Vaccine Research

The 12th Annual Conference on Vaccine Research is sponsored by The National Foundation for Infectious Diseases (NFID), a non-profit, tax-exempt (501c3) organization founded in 1973 and dedicated to educating the public and healthcare professionals about the causes, treatment and prevention of infectious diseases. The Annual Conference has become the largest scientific meeting devoted exclusively to research on vaccines and associated technologies for disease prevention and treatment through immunization. The Conference provides high-quality, current reports of scientific progress featured in both invited presentations and submitted abstracts. The disparate fields covered in both human and veterinary vaccinology encourage valuable cross-fertilization of ideas and approaches among researchers otherwise focused on specific ideas or methods.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs includ
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 EPFL and the University of  ... of John P. Donoghue . The American neuroscientist ... . The new Wyss Center for ... Geneva , has named as its director ... P. Donoghue , founder of Brown University,s Institute for ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. ... developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), ... nutritional products in the People,s Republic of China, today ... December 31, 2010. Fiscal 2010 Financial ...
... Although top bio-pharmaceutical companies agree that Key Opinion ... a new product, increasing competition has made it difficult ... role of Medical Science Liaisons (MSLs) in forging relationships ... years. In fact, today, MSL ...
... 2011 Reportlinker.com announces that a new market ... Global Angiongenesis Inhibitors and ... This report analyzes the ... in US$ Million by the following product ...
Cached Biology Technology:Weikang Bio-Technology Announces Fiscal 2010 Financial Results 2Weikang Bio-Technology Announces Fiscal 2010 Financial Results 3Weikang Bio-Technology Announces Fiscal 2010 Financial Results 4Weikang Bio-Technology Announces Fiscal 2010 Financial Results 5Weikang Bio-Technology Announces Fiscal 2010 Financial Results 6Weikang Bio-Technology Announces Fiscal 2010 Financial Results 7Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 2Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 3Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 4Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 5Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 6Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 7Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 8Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 9Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 10Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 11Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 12Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 13Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 14Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 15Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 16Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry 17
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... , BOSTON -- October 17, 2011-- In a paper published ... headed by Mary R. Loeken, PhD, has identified the enzyme AMP ... the risk of neural tube defects such as spina bifida and ... Even if women with diabetes -- either type 1 or ...
... polyester which occurs naturally in bacteria as Ralstonia ... PHB is biodegradable and is not dependent on fossil ... produce to replace petroleum-based plastics. New research reported in ... describes an alternative method of producing PHB in ...
... have found a way to inject a precise dose of ... without a needle. The technique uses electricity to "shoot" ... a cell in a fraction of a second. L. ... the technique in the online edition of the journal ...
Cached Biology News:Joslin study finds clue to birth defects in babies of mothers with diabetes 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3
Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....
Request Info...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
...
Biology Products: